Bispecific antibody against human CD19 and β-Gal - Negative control
| Product | Unit size | Cat. code | Docs. | Qty. | Price | |
|---|---|---|---|---|---|---|
|
Anti-hCD19-βGal Bispecific antibody against human CD19 and β-galactosidase; Negative control |
Show product |
10 µg |
bimab-cd19bg-01
|
|
Notification: The cat. code has been changed from bimab-hcd19bgal to bimab-cd19bg-01.
Anti-hCD19-βGal binds to hCD19 on B cells but not to hCD3 on T cells
Monoclonal scFv antibody against human CD19 and β-galactosidase; Negative control
Anti-hCD19-βGal is a bispecific antibody that binds to two sites: hCD19 expressed on the surface of B cells, and E. coli β-galactosidase (β-Gal). It is used as a negative control for Anti-hCD19-CD3 bispecific antibody that, like Blinatumomab, engages unstimulated T cells to proliferate and exert cytotoxic activity on CD19-positive lymphoma cells [1,2].
References:
1. Krishnamurthy A. & Jimeno A., 2017. Bispecific antibodies for cancer therapy: A review. Pharmacol Ther. S0163-7258(17)30293-0.
2. Bargou R. et al., 2008. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell– Engaging Antibody. Science. 321(5891):974-7.
Figures
Specifications
Clonality: Monoclonal antibody.
Specificity: human CD19 and E. coli β-galactosidase (β-Gal).
Isotype: none (scFv).
Source: CHO (Chinese hamster ovary) cells.
Purity: Purified by affinity chromatography.
Quality control:
- Binding to hCD19 has been confirmed by flow cytometry.
- The inability of Anti-hCD19-βGal to induce T cell activation has been confirmed using cellular assays.
- The complete sequence of this antibody has been verified.
- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
Contents
10 µg Anti-hCD19-βGal, purified antibody, provided azide-free and lyophilized.
Product is shipped at room temperature.
Store lyophilized antibody at -20°C.
Lyophilized product is stable for at least 1 year.